CLDN18.2 in oesophageal cancer
1 EU-approved indication in oesophageal cancer needs a CLDN18.2 result: zolbetuximab (1st line, advanced).
Histology
| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| CLDN18.2-positive1 | ||||
Vyloy | Claudin (CLDN) 18.2 positive, HER2-negative | + fluoropyrimidine- and platinum-containing chemotherapy | 1L advanced | Gastro-oesophageal junction adenocarcinoma only |
4 approvals for Oesophageal need no biomarker and apply whatever the result. All approvals for Oesophageal
See also
Label wording1
The sentence from section 4.1 of the SmPC that each indication above comes from.
- Zolbetuximab (Vyloy)
Vyloy, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma whose tumours are Claudin (CLDN) 18.2 positive (see section 4.2).